NuvaHealth Review
Appears to have shut downNuvaHealth is closed and is not taking new patients. It published only a first-month price, $139.
Some of the links on this page earn us money. If you sign up with a provider after following one, that provider may pay GLP Watchdog a commission. Learn more
NuvaHealth is no longer taking new patients. This program appears to have shut down, so we're not linking to it. Here are the top-rated GLP-1 providers we recommend instead.
Last published price before it closed: $139/mo. No longer offered.
See our top-rated GLP-1 providers →NuvaHealth advertised compounded semaglutide and tirzepatide. Its site is offline. In October 2026 the domain returned a Cloudflare error on every request, and its storefront no longer existed.
Vetted alternatives to NuvaHealth
Embody
Best for: a flat compounded tirzepatide or semaglutide price at every dose, from a seller that names its pharmacies
Editorial score · methodology
Collective
Best for: flat any-dose pricing, if you can absorb a $199 annual membership on top
Editorial score · methodology
AgelessRx
Best for: microdosed compounded GLP-1s from a longevity clinic, or brand Wegovy at manufacturer pricing plus monitoring
Editorial score · methodology
NuvaHealth at a glance
- Status
- Closed: not taking new patients
- Type
- GLP-1 telehealth provider
- Medications
- Semaglutide, Tirzepatide
- Last published price
- $139/mo (first month; ongoing price shown at checkout (month two))
- What it included
- Medication · Shipping
- FDA status
- No FDA warning letters found
How NuvaHealth scores
NuvaHealth has closed. These scores describe what it published when we last checked it, before it stopped taking patients.
Six columns, each one computed from something NuvaHealth published rather than from an opinion we formed: what it charges, which molecules it will dispense, what its record shows, and what the monthly figure actually buys. Where a seller keeps something back, such as its price or its pharmacy, the score reflects it. Every seller we review goes through the same six columns.
Value25%
3.0/10The listed figure is not a comparable monthly price for a named GLP-1 (it may be a membership fee, an insured copay, a per-vial rate or a starting-dose price), so Value is capped rather than scored against other sellers.
Effectiveness25%
10.0/10Dispenses semaglutide and tirzepatide, including the FDA-approved product. Anchored to SURMOUNT-1 (tirzepatide, -20.9%) and STEP 1 (semaglutide, -14.9%).
User Experience15%
8.0/10A price is shown before the questionnaire starts.
Trust & Safety15%
6.5/10No pharmacy is named for its prescriptions. It shows a price before asking for health information.
Accessibility10%
5.0/10No state list is available to check, so this is held at the midpoint rather than scored on reach.
Support10%
4.5/10The price covers the medication and shipping.
A seller that shows no price until after the medical intake loses points on User Experience and Trust & Safety, and its review says so. How we score →
What we checked on NuvaHealth
Last checked July 2026- Checked the listed price across 7 dose or plan tiers
- Checked what the monthly price covers, and what it leaves out
- Checked FDA warning letters for NuvaHealth
Price, availability, and compliance here are read off the seller's own pages and off primary regulatory records, named in the sources below.
Medications NuvaHealth listed
NuvaHealth listed Wegovy, Ozempic, Mounjaro, compounded semaglutide and compounded tirzepatide. Each one has its own guide: how it works, the dosing schedule, the side effects that show up in practice, and what the trials measured.
Prices it published before closing
Prices re-verified
first month; ongoing price shown at checkout (month two)
first month; ongoing price shown at checkout (month two)
first month; ongoing price shown at checkout (month two)
first month; ongoing price shown at checkout (month two)
first month; ongoing price shown at checkout (month two)
first month; ongoing price shown at checkout (month two)
first month; ongoing price shown at checkout (month two)
In its favor
- Showed its price before the medical questionnaire, so you could compare it without handing over health information
- The monthly price included the medication and shipping
- We found no FDA warning letters issued to NuvaHealth
Against it
- Its compounded semaglutide and tirzepatide are not FDA-approved, so they have not been reviewed by the agency for safety, effectiveness or manufacturing quality
NuvaHealth is no longer taking new patients. What follows describes the program as it last ran, for anyone comparing it with a seller that is still open.
What NuvaHealth charged
NuvaHealth advertises $139 as an introductory price and does not publish what later months cost. Ask for the ongoing monthly price before you pay, because that is the number to compare.
- Compounded semaglutide: $139 for the first month
- Semaglutide: $179 for the first month
- Compounded tirzepatide: $229 for the first month
- Tirzepatide: $239 for the first month
- Ozempic: $1,159 for the first month
- Wegovy: $1,179 for the first month
Ivim Health, at about $140/month, is the closest like-for-like alternative we review.
What NuvaHealth dispensed
NuvaHealth prescribed semaglutide (approved as Wegovy and Ozempic) and tirzepatide (approved as Zepbound and Mounjaro). Between them these are the pair carrying the strongest published outcome data. The choice is between an FDA-approved pen and a compounded preparation that costs less. Compounding is lawful and often appropriate, but a compounded product is not an approved one, and the price gap is largely that difference.
Safety and disclosure
NuvaHealth told buyers its price before the medical questionnaire. It also offered clinician messaging between visits. We found no FDA warning letters issued to NuvaHealth. How we weigh oversight, disclosure and price is set out in our scoring methodology.
Our read
NuvaHealth is no longer taking new patients, so the choice is among the sellers that are still open.
The Bottom Line
NuvaHealth is closed and is not taking new patients. It published only a first-month price, $139.
Where NuvaHealth is the wrong choice
No seller suits every reader, and pretending otherwise is the easiest way to sell one. On these two counts, another seller does better.
- If the standing monthly cost is what decides it, consider WellMedRx (from $49/mo).
- If you want a human checking in, not just a prescription, consider Eden.
If none of these fits, our guide to alternatives to NuvaHealth sets more sellers in the same category beside NuvaHealth on price, states and what the price includes.
Frequently Asked Questions
Glossary
The words sellers use, defined. Tap any term.
- Semaglutide · Drugs and brands
- Tirzepatide · Drugs and brands
- Compounded GLP-1 · Pharmacy and drug forms
- 503A pharmacy · Pharmacy and drug forms
- PCAB accreditation · Pharmacy and drug forms
- Prior authorization (PA) · Insurance and regulatory
- Off-label use · Insurance and regulatory
- FDA Drug Shortage List · Insurance and regulatory
Sources
Cited across this NuvaHealth review: primary regulatory filings, and peer-reviewed studies.
Sources & methodology — as of July 2026
- 1.GLP Watchdog — GLP-1 Pricing Index 2026 (our independent dataset)— GLP Watchdog.
- 2.FDA — Compounding and the 503A Pharmacy Framework— U.S. Food & Drug Administration.
- 3.FDA — Drug Shortages Database (current shortage listings)— U.S. Food & Drug Administration.
- 4.PCAB — Pharmacy Compounding Accreditation Board Standards— Accreditation Commission for Health Care (ACHC) / PCAB.
- 5.KFF — Medicaid coverage research (anti-obesity & GLP-1 drug policy)— Kaiser Family Foundation.
- 6.STEP 1 Trial — Once-Weekly Semaglutide in Adults with Overweight or Obesity (Wilding JPH et al.)— New England Journal of Medicine.PMID: 33567185.
- 7.FDA — Wegovy (semaglutide) Approval History via Drugs@FDA— U.S. Food & Drug Administration.
- 8.FDA — Ozempic (semaglutide) Prescribing Information via Drugs@FDA— U.S. Food & Drug Administration.
- 9.SURMOUNT-1 Trial — Tirzepatide Once Weekly for the Treatment of Obesity (Jastreboff AM et al.)— New England Journal of Medicine.PMID: 35658024.
- 10.FDA — Zepbound (tirzepatide) Approval History via Drugs@FDA— U.S. Food & Drug Administration.
- 11.FDA — Mounjaro (tirzepatide) Prescribing Information via Drugs@FDA— U.S. Food & Drug Administration.
- 12.SURMOUNT-5 Trial — Tirzepatide vs. Semaglutide Head-to-Head in Obesity (Aronne LJ et al.)— New England Journal of Medicine.PMID: 40353578.